Kolon Pharma, Dongbang Medical to export medical threads to Brazil

Through local partner, they plan to supply over $18 mn worth of medical threads to the world's second-largest aesthetic market

Kolon Pharma, Dongbang Medical to export medical threads to Brazil
Ji-Hyun Lee 1
2023-07-27 16:29:35 bluesky@hankyung.com
Bio & Pharma

Kolon Pharma, the pharmaceutical affiliate of South Korea's Kolon Group, announced on Thursday that it has signed a business agreement with Dongbang Medical, a specialized medical device company, to enter the Brazilian aesthetic market.

Brazil is the world's second-largest aesthetic market. Kolon Pharma and Dongbang Medical plan to supply medical threads used in aesthetic surgical procedures, totaling over $18 million, for a period of five years. Dongbang Medical will be responsible for production, while Kolon Pharma will handle distribution. The two companies plan to diversify distribution channels to gradually expand their market share.

"The Brazilian aesthetic market is the second-largest in the world and will play a crucial role in our company's global expansion. With our entry into the Brazilian market, we aim to actively pursue opportunities for further global expansion in the pharmaceutical industry," said Jeon Jae-kwang, CEO of Kolon Pharma.

During the agreement ceremony, the three companies pledged to donate $10,000 from the sales revenue of Brazilian aesthetic products to support the treatment of domestic children with facial disorders, totaling $30,000. "In line with our global business expansion, we are committed to actively engaging in various social contribution activities as part of our ESG management," a Kolon Pharma source said.  

Write to Ji-Hyun Lee at bluesky@hankyung.com

GC Biopharma inks $90mn deal for blood products in Brazil

GC Biopharma inks $90mn deal for blood products in Brazil

Huh Eun-chul, CEO of GC Biopharma (left) and Marcelo Rodolfo Hahn, CEO of Blau Farmacêutica South Korea's GC Biopharma Co. on Monday announced on Monday that it has a supply contract with Blau Farmacêutica, a Brazilian pharmaceutical firm, for its IVIG-SN 5% blood product. The

Celltrion Healthcare launches Remsima SC in Brazil

Celltrion Healthcare launches Remsima SC in Brazil

Celltrion's Remsima South Korean biopharmaceutical company Celltrion Healthcare Co. revealed on Monday its introduction of Remsima SC, a treatment for autoimmune diseases, in Brazil, the largest pharmaceutical market in Latin America. The company received approval from the Brazilian Health

Kolon Pharma to merge with anti-cancer drug developer Platbio

Kolon Pharma to merge with anti-cancer drug developer Platbio

Jeon Jae-kwang, CEO of Kolon Pharma (second from left) and Kim Sun-jin, CEO of Platbio (third) Kolon Pharma, the pharmaceutical affiliate of South Korea's Kolon Group, is merging with anti-cancer drug developer Platbio to advance the development of new medicines through better distribution capa

Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico

Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico

Daewoong Pharmaceutical headquarters in Seoul (Courtesy of Daewoong) South Korea’s Daewoong Pharmaceutical Co. said on Feb. 24 it is set to embark on global sales of Envlo, a new drug for diabetes, by exporting it to Brazil and Mexico.Through the $84.4 million deal, the Korean biotech w

Brazil approves Celltrion Pharm’s syringe facility

Brazil approves Celltrion Pharm’s syringe facility

Celltrion Pharm's Cheongju plant in South Korea Celltrion Pharm Inc., a South Korean biopharmaceutical company, said on Monday it received certification from Brazil’s health regulator for its pre-filled syringe production facility.The company said it passed an inspection by Brazil’s

Lunit exports AI imaging analysis solution to Brazil

Lunit exports AI imaging analysis solution to Brazil

South Korea's medical imaging startup Lunit said on Monday it has signed a software licensing agreement with Albert Einstein Israelite Hospital in Sao Paulo, Brazil, for its Lunit Insight CXR, an artificial intelligence (AI) imaging analysis solution for chest X-rays.Einstein Hospital repres

SK Biopharmaceuticals signs epilepsy drug deal with Brazil’s Eurofarma

SK Biopharmaceuticals signs epilepsy drug deal with Brazil’s Eurofarma

SK Biopharm researchers South Korea’s SK Biopharmaceuticals Co. has signed a deal to license out its technology for Cenobamate, an antiepileptic drug, to Brazil’s Eurofarma Laboratórios S.A. to enter the Latin American market.With the technology transfer, SK aims to sell

(* comment hide *}